TÃœBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a world biopharmaceutical firm creating a brand new class of transformative medicines based mostly on messenger ribonucleic acid (“mRNA”), will report monetary outcomes, and supply enterprise updates for the third quarter and first 9 months 2024 on Tuesday, November 12, 2024. The corporate will host a convention name and webcast on the identical day at
3 p.m. CET / 9 a.m. EST.
Dial-in numbers to take part within the convention name:
U.S. Toll-Free: +1-877-407-0989
Worldwide: +1-201-389-0921
Germany: 0800-182-0040 (landline entry) / 0800-184-4713 (mobile phone entry)
The dwell webcast hyperlink might be accessed by way of the newsroom part of the CureVac web site at https://www.curevac.com/en/newsroom/occasions/
Corresponding presentation slides will probably be posted shortly earlier than the beginning of the webcast. A replay will probably be made obtainable at this web site after the occasion.
About CureVac
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech firm based in 2000 to advance the sector of messenger RNA (mRNA) know-how for software in human medication. In additional than 20 years of creating, optimizing, and manufacturing this versatile organic molecule for medical functions, CureVac has launched and refined key underlying applied sciences that had been important to the manufacturing of mRNA vaccines towards COVID-19, and is at present laying the groundwork for software of mRNA in new therapeutic areas of main unmet want. CureVac is leveraging mRNA know-how, mixed with superior omics and computational instruments, to design and develop off-the-shelf and customized most cancers vaccine product candidates. It additionally develops packages in prophylactic vaccines and in remedies that allow the human physique to supply its personal therapeutic proteins. Headquartered in Tübingen, Germany, CureVac additionally operates websites within the Netherlands, Belgium, Switzerland, and the U.S. Additional data might be discovered at www.curevac.com.
CureVac Media and Investor Relations Contact
Dr. Sarah Fakih, Vice President Company Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
Ahead-Wanting Statements of CureVac
This press launch comprises statements that represent “forward looking statements” as that time period is outlined in the US Personal Securities Litigation Reform Act of 1995, together with statements that specific the opinions, expectations, beliefs, plans, targets, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Company Companies GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the “company”) concerning future occasions or future outcomes, in distinction with statements that mirror historic information. Examples embody dialogue of the potential efficacy of the corporate’s vaccine and therapy candidates and the corporate’s methods, financing plans, money runway expectations, progress alternatives and market progress. In some instances, you’ll be able to establish such forward-looking statements by terminology akin to “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the unfavourable of those phrases or comparable expressions. Ahead-looking statements are based mostly on administration’s present beliefs and assumptions and on data at present obtainable to the corporate. Nevertheless, these forward-looking statements will not be a assure of the corporate’s efficiency, and you shouldn’t place undue reliance on such statements. Ahead-looking statements are topic to many dangers, uncertainties and different variable circumstances, together with unfavourable worldwide financial situations and ongoing instability and volatility within the worldwide monetary markets, means to acquire funding, means to conduct present and future preclinical research and scientific trials, the timing, expense and uncertainty of regulatory approval, reliance on third events and collaboration companions, means to commercialize merchandise, means to fabricate any merchandise, potential modifications in present and proposed laws, laws and governmental insurance policies, pressures from growing competitors and consolidation within the firm’s trade, the results of the COVID-19 pandemic on the corporate’s enterprise and outcomes of operations, means to handle progress, reliance on key personnel, reliance on mental property safety, means to offer for affected person security, fluctuations of working outcomes because of the impact of alternate charges, delays in litigation proceedings, completely different judicial outcomes or different elements. Such dangers and uncertainties could trigger the statements to be inaccurate and readers are cautioned to not place undue reliance on such statements. Many of those dangers are exterior of the corporate’s management and will trigger its precise outcomes to vary materially from these it thought would happen. The forward-looking statements included on this press launch are made solely as of the date hereof. The corporate doesn’t undertake, and particularly declines, any obligation to replace any such statements or to publicly announce the outcomes of any revisions to any such statements to mirror future occasions or developments, besides as required by legislation.
For additional data, please reference the corporate’s studies and paperwork filed with the U.S. Securities and Alternate Fee (the “SEC”). You could get these paperwork by visiting EDGAR on the SEC web site at www.sec.gov.
SOURCE: CureVac
View the unique press launch on accesswire.com
